In vivo, subcutaneous tumor volume increased with METTL13 overexpression and decreased with shMETTL13 treatment and docetaxel (10 mg/kg) administered via intraperitoneal injection twice weekly (Fig. 5N, O, P and Q). Here, METTL13 is linked to neoplasm.